Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on the current receivership proceedings.
To enable the Company to continue its search for new investors or partners to support its new development plan in STEMI (ST-Elevation Myocardial Infarction), the court-appointed administrator had granted mid-October 2024 an extension until Tuesday November 5, 2024, to the call for bids published on September 13, for a continuation or disposal plan.
To date, the court-appointed administrator has received no proposal from a buyer. The Company is therefore pursuing its search for a solution to support the development of glenzocimab in STEMI, and the 6-month observation period opened on August 6, 2024, is ongoing.
As a reminder, on 6 August 2024, the Paris Commercial Court had ordered the opening of receivership proceedings. The purpose of these proceedings is to enable the Company to assess all the options available to it to pursue its development, the development of its product, glenzocimab, and its search for financing and partners. As already mentioned, this procedure will also enable the Company to finance its operations until January 2025.
The Company will continue to keep the market informed of developments in the current receivership proceedings and calls on investors to follow closely future communications concerning its progress.
About ACTICOR BIOTECH
ACTICOR BIOTECH, a clinical-stage biopharmaceutical company founded in 2013 from the work of INSERM, is developing glenzocimab, a humanized monoclonal antibody fragment (fab) targeting the GPVI platelet receptor for the treatment of cardiovascular emergencies and acute thrombotic diseases.
The main clinical indication being evaluated is acute ischemic stroke, due to the strong need for safer treatments, particularly those that do not increase the risk of bleeding, and its high incidence. In three international clinical trials involving over 600 stroke patients, no significant impact on neurological improvement (mRS score at 3 months) was demonstrated, with the exception of a sub-population of patients with intracerebral haemorrhage, where mortality was significantly reduced by a factor of 3 (p=0.035) (Mazighi et al. 2024).
LIBERATE, a Phase 2 clinical trial in the acute phase of myocardial infarction (STEMI), is currently being recruited through an academic partnership with the University of Birmingham (UK). This study aims to demonstrate the efficacy of glenzocimab in reducing the size of myocardial infarction, a critical factor for long-term cardiac function.
In all, more than 800 subjects were included in the clinical trials, over 400 of whom were exposed to glenzocimab without safety concerns.
The use of glenzocimab in thrombotic diseases is covered by 3 patent families, with an expiry date in 2036 for the first family. ACTICOR BIOTECH also has the right to develop a biomarker for stroke patients.
Acticor Biotech is backed by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 ALACT).
For further information, visit: www.acticor-biotech.com
Disclaimer
This press release contains forward-looking statements with respect to Acticor Biotech and its business. Acticor Biotech believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in such forward-looking statements will prove to have been correct, as they are subject to risks, including those described in the Universal Registration Document as filed with the Autorité des marchés financiers on July 9, 2024, and to changes in economic conditions, financial markets and the markets in which Acticor Biotech operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Acticor Biotech or that Acticor Biotech does not currently consider material. The occurrence of some or all of these risks could cause Acticor Biotech's actual results, financial condition, performance or achievements to differ materially from those expressed in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105824773/en/
Contacts:
ACTICOR BIOTECH
Gilles AVENARD, MD
CEO and Founder
gilles.avenard@acticor-biotech.com
Sophie BINAY, PhD
General Manager and CSO
Sophie.binay@acticor-biotech.com
NewCap
Mathilde BOHIN
Investor Relations
acticor@newcap.eu
T. : +33 (0)1 44 71 94 95
NewCap
Arthur ROUILLÉ
Media Relations
acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
